Crossmark

Immuno-PET Monitoring of CD8+ T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a 89Zr Anti-CD8+ Mouse Minibody in EMT6 Syngeneic Tumor Mouse

Crossref DOI link: https://doi.org/10.1007/s11307-022-01781-7

Published Online: 2022-10-20

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alsaid, Hasan https://orcid.org/0000-0001-6600-2146
Cheng, Shih-Hsun

Bi, Meixia

Xie, Fang

Rambo, Mary

Skedzielewski, Tinamarie

Hoang, Bao

Mohanan, Sunish

Comroe, Debra

Gehman, Andrew

Hsu, Chih-Yang

Farhangi, Kamyar

Tran, Hoang

Sherina, Valeriia

Doan, Minh

Groseclose, M. Reid

Hopson, Christopher B.

Brett, Sara

Wilson, Ian A.

Nicholls, Andrew

Ballas, Marc

Waight, Jeremy D.

Jucker, Beat M.
License Information

Text and Data Mining valid from 2022-10-20

Version of Record valid from 2022-10-20
More Information

Article History

Received: 29 May 2022

Revised: 15 September 2022

Accepted: 11 October 2022

First Online: 20 October 2022

Declarations

:

: HA, S-HC, FX, MR, TS, BH, DC, AG, CY-H, KF, HT, VS, MD, RG, CBH, AN, MB, JDW, and BMJ are employees of GSK. SB, MBi, and SM are former employees of GSK. IW is an employee of ImaginAb.

Document is current

Any future updates will be listed below